SOL-GEL TECHN Ownership
4SG Stock | EUR 0.49 0.02 4.26% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
SOL-GEL |
SOL-GEL Stock Ownership Analysis
About 74.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel. SOL GEL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 65 people. For more info on SOL GEL TECHN IS 10 please contact Alon SeriLevy at 972 8 931 3433 or go to http://www.sol-gel.com.Currently Active Assets on Macroaxis
Other Information on Investing in SOL-GEL Stock
SOL-GEL TECHN financial ratios help investors to determine whether SOL-GEL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SOL-GEL with respect to the benefits of owning SOL-GEL TECHN security.